

Michael S Kinch

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9067066/michael-s-kinch-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

100
papers

5,657
citations

43
h-index

74
g-index

101
ext. papers

6,099
ext. citations

7.6
avg, IF

5.74
L-index

| # | Paper | IF | Citations |
|-----|---|------|-----------|
| 100 | 2021 in review: FDA approvals of new medicines.. <i>Drug Discovery Today</i> , 2022 , | 8.8 | 3 |
| 99 | Sources of innovation for new medicines: questions of sustainability. <i>Drug Discovery Today</i> , 2021 , 26, 240-247 | 8.8 | 3 |
| 98 | 2020 in review: FDA approvals of new medicines. <i>Drug Discovery Today</i> , 2021 , 26, 2794-2799 | 8.8 | 1 |
| 97 | Rising Academic Contributions to Drug Development: Evidence of Vigor or Trauma?. <i>ACS Pharmacology and Translational Science</i> , 2020 , 3, 1427-1429 | 5.9 | 0 |
| 96 | Oh, the Frustration of Antibodies!. <i>ACS Pharmacology and Translational Science</i> , 2020 , 3, 1035-1036 | 5.9 | 1 |
| 95 | 2019 in review: FDA approvals of new medicines. <i>Drug Discovery Today</i> , 2020 , 25, 1923-1923 | 8.8 | 1 |
| 94 | Expanding roles for academic entrepreneurship in drug discovery. <i>Drug Discovery Today</i> , 2020 , 25, 1905-1905 | 8.8 | 3 |
| 93 | Assessing the public landscape of clinical-stage pharmaceuticals through freely available online databases. <i>Drug Discovery Today</i> , 2019 , 24, 1010-1016 | 8.8 | 6 |
| 92 | 2018 in review: FDA approvals of new molecular entities. <i>Drug Discovery Today</i> , 2019 , 24, 1710-1714 | 8.8 | 6 |
| 91 | CDEK: Clinical Drug Experience Knowledgebase. <i>Database: the Journal of Biological Databases and Curation</i> , 2019 , 2019, | 5 | 6 |
| 90 | Lost medicines: a longer view of the pharmaceutical industry with the potential to reinvigorate discovery. <i>Drug Discovery Today</i> , 2019 , 24, 382-389 | 8.8 | 6 |
| 89 | 2017 in review: FDA approvals of new molecular entities. <i>Drug Discovery Today</i> , 2018 , 23, 1469-1473 | 8.8 | 16 |
| 88 | 2014 in review: FDA approval of new drugs. <i>Drug Discovery Today</i> , 2017 , 22, 620-624 | 8.8 | 2 |
| 87 | Analysis of FDA-approved imaging agents. <i>Drug Discovery Today</i> , 2017 , 22, 1077-1083 | 8.8 | 11 |
| 86 | An overview of FDA-approved vaccines & their innovators. <i>Expert Review of Vaccines</i> , 2017 , 16, 1253-1265. | 5.2 | 15 |
| 85 | Food and microbiota in the FDA regulatory framework. <i>Science</i> , 2017 , 357, 39-40 | 33.3 | 21 |
| 84 | NIH Support for FDA-Approved Medicines. <i>Cell Chemical Biology</i> , 2017 , 24, 1315-1316 | 8.2 | 2 |

| | | | |
|----|--|-----|-----|
| 83 | 2016 in review: FDA approvals of new molecular entities. <i>Drug Discovery Today</i> , 2017 , 22, 1593-1597 | 8.8 | 12 |
| 82 | Innovator Organizations in New Drug Development: Assessing the Sustainability of the Biopharmaceutical Industry. <i>Cell Chemical Biology</i> , 2016 , 23, 644-53 | 8.2 | 10 |
| 81 | An analysis of FDA-approved drugs for cardiovascular diseases. <i>Drug Discovery Today</i> , 2016 , 21, 1-4 | 8.8 | 6 |
| 80 | An analysis of FDA-approved drugs: natural products and their derivatives. <i>Drug Discovery Today</i> , 2016 , 21, 204-7 | 8.8 | 389 |
| 79 | Prescription for Change 2016 , | | 6 |
| 78 | 2015 in review: FDA approval of new drugs. <i>Drug Discovery Today</i> , 2016 , 21, 1046-50 | 8.8 | 13 |
| 77 | An analysis of FDA-approved drugs for inflammation and autoimmune diseases. <i>Drug Discovery Today</i> , 2015 , 20, 920-3 | 8.8 | 12 |
| 76 | An analysis of original research contributions toward FDA-approved drugs. <i>Drug Discovery Today</i> , 2015 , 20, 1182-7 | 8.8 | 30 |
| 75 | A history of drug development in four acts. <i>Drug Discovery Today</i> , 2015 , 20, 1163-8 | 8.8 | 3 |
| 74 | An analysis of FDA-approved drugs for neurological disorders. <i>Drug Discovery Today</i> , 2015 , 20, 1040-3 | 8.8 | 17 |
| 73 | Sources of innovation: an assessment of intellectual property. <i>Drug Discovery Today</i> , 2015 , 20, 500-4 | 8.8 | 3 |
| 72 | New drug discovery: extraordinary opportunities in an uncertain time. <i>Drug Discovery Today</i> , 2015 , 20, 1288-92 | 8.8 | 7 |
| 71 | Post-approval fate of pharmaceutical companies. <i>Drug Discovery Today</i> , 2015 , 20, 170-4 | 8.8 | 2 |
| 70 | Target selection for FDA-approved medicines. <i>Drug Discovery Today</i> , 2015 , 20, 784-9 | 8.8 | 17 |
| 69 | An overview of FDA-approved biologics medicines. <i>Drug Discovery Today</i> , 2015 , 20, 393-8 | 8.8 | 104 |
| 68 | An analysis of FDA-approved drugs for psychiatric disorders. <i>Drug Discovery Today</i> , 2015 , 20, 292-5 | 8.8 | 3 |
| 67 | An analysis of FDA-approved drugs for metabolic diseases. <i>Drug Discovery Today</i> , 2015 , 20, 648-51 | 8.8 | 6 |
| 66 | An analysis of FDA-approved drugs for pain and anesthesia. <i>Drug Discovery Today</i> , 2015 , 20, 3-6 | 8.8 | 4 |

| | | | |
|----|---|------|-----|
| 65 | An overview of FDA-approved new molecular entities: 1827-2013. <i>Drug Discovery Today</i> , 2014 , 19, 1033-8 | 8.8 | 152 |
| 64 | An analysis of FDA-approved drugs for infectious disease: antibacterial agents. <i>Drug Discovery Today</i> , 2014 , 19, 1283-7 | 8.8 | 101 |
| 63 | The rise (and decline?) of biotechnology. <i>Drug Discovery Today</i> , 2014 , 19, 1686-1690 | 8.8 | 24 |
| 62 | Trends in pharmaceutical targeting of clinical indications: 1930-2013. <i>Drug Discovery Today</i> , 2014 , 19, 1682-1685 | 8.8 | 20 |
| 61 | An analysis of FDA-approved drugs for infectious disease: HIV/AIDS drugs. <i>Drug Discovery Today</i> , 2014 , 19, 1510-3 | 8.8 | 43 |
| 60 | An analysis of FDA-approved drugs for oncology. <i>Drug Discovery Today</i> , 2014 , 19, 1831-5 | 8.8 | 53 |
| 59 | Dual targeting of EphA2 and ER restores tamoxifen sensitivity in ER/EphA2-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2011 , 127, 375-84 | 4.4 | 29 |
| 58 | Antiviral activity of a small-molecule inhibitor of filovirus infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2010 , 54, 2152-9 | 5.9 | 60 |
| 57 | Function-first approaches to improve target identification in cancer. <i>Future Oncology</i> , 2009 , 5, 617-23 | 3.6 | 3 |
| 56 | The use of Random Homozygous Gene Perturbation to identify novel host-oriented targets for influenza. <i>Virology</i> , 2009 , 387, 473-81 | 3.6 | 66 |
| 55 | Development of a broad-spectrum antiviral with activity against Ebola virus. <i>Antiviral Research</i> , 2009 , 83, 245-51 | 10.8 | 74 |
| 54 | Identification of novel host-oriented targets for Human Immunodeficiency Virus type 1 using Random Homozygous Gene Perturbation. <i>Virology Journal</i> , 2009 , 6, 154 | 6.1 | 4 |
| 53 | Antibody-dependent cell-mediated cytotoxicity effector-enhanced EphA2 agonist monoclonal antibody demonstrates potent activity against human tumors. <i>Neoplasia</i> , 2009 , 11, 509-17, 2 p following 517 | 6.4 | 27 |
| 52 | FGI-104: a broad-spectrum small molecule inhibitor of viral infection. <i>American Journal of Translational Research (discontinued)</i> , 2009 , 1, 87-98 | 3 | 35 |
| 51 | Tumor-selective response to antibody-mediated targeting of alphavbeta3 integrin in ovarian cancer. <i>Neoplasia</i> , 2008 , 10, 1259-67 | 6.4 | 94 |
| 50 | A human antibody-drug conjugate targeting EphA2 inhibits tumor growth in vivo. <i>Cancer Research</i> , 2008 , 68, 9367-74 | 10.1 | 109 |
| 49 | EphA2 overexpression promotes ovarian cancer growth. <i>Cancer Biology and Therapy</i> , 2008 , 7, 1098-103 | 4.6 | 47 |
| 48 | Enhancement in specific CD8+ T cell recognition of EphA2+ tumors in vitro and in vivo after treatment with ligand agonists. <i>Journal of Immunology</i> , 2008 , 181, 7721-7 | 5.3 | 24 |

| | | | |
|----|--|------|-----|
| 47 | Selective targeting and potent control of tumor growth using an EphA2/CD3-Bispecific single-chain antibody construct. <i>Cancer Research</i> , 2007 , 67, 3927-35 | 10.1 | 77 |
| 46 | EphA2 overexpression is associated with angiogenesis in ovarian cancer. <i>Cancer</i> , 2007 , 109, 332-40 | 6.4 | 88 |
| 45 | Analysis of EphA2 expression and mutant p53 in ovarian carcinoma. <i>Cancer Biology and Therapy</i> , 2006 , 5, 1357-60 | 4.6 | 17 |
| 44 | VE-cadherin regulates EphA2 in aggressive melanoma cells through a novel signaling pathway: implications for vasculogenic mimicry. <i>Cancer Biology and Therapy</i> , 2006 , 5, 228-33 | 4.6 | 141 |
| 43 | Direct targeting of alphavbeta3 integrin on tumor cells with a monoclonal antibody, Abegrin. <i>Molecular Cancer Therapeutics</i> , 2006 , 5, 3122-9 | 6.1 | 83 |
| 42 | Expression of EphA2 and Ephrin A-1 in carcinoma of the urinary bladder. <i>Clinical Cancer Research</i> , 2006 , 12, 353-60 | 12.9 | 91 |
| 41 | Efficacy and antivasular effects of EphA2 reduction with an agonistic antibody in ovarian cancer. <i>Journal of the National Cancer Institute</i> , 2006 , 98, 1558-70 | 9.7 | 108 |
| 40 | Expression and purification of the intact cytoplasmic domain of the human ephrin receptor A2 tyrosine kinase in Escherichia coli. <i>Protein Expression and Purification</i> , 2006 , 47, 210-6 | 2 | 4 |
| 39 | EphA2 as a target for ovarian cancer therapy. <i>Expert Opinion on Therapeutic Targets</i> , 2005 , 9, 1179-87 | 6.4 | 73 |
| 38 | Expression of EphA2 is prognostic of disease-free interval and overall survival in surgically treated patients with renal cell carcinoma. <i>Clinical Cancer Research</i> , 2005 , 11, 226-31 | 12.9 | 63 |
| 37 | PC cell-derived growth factor expression in prostatic intraepithelial neoplasia and prostatic adenocarcinoma. <i>Clinical Cancer Research</i> , 2004 , 10, 1333-7 | 12.9 | 66 |
| 36 | Loss of 14-3-3sigma in prostate cancer and its precursors. <i>Clinical Cancer Research</i> , 2004 , 10, 3064-8 | 12.9 | 85 |
| 35 | EphA2 expression is associated with aggressive features in ovarian carcinoma. <i>Clinical Cancer Research</i> , 2004 , 10, 5145-50 | 12.9 | 181 |
| 34 | Decreased tumorigenic potential of EphA2-overexpressing breast cancer cells following treatment with adenoviral vectors that express EphrinA1. <i>Cancer Gene Therapy</i> , 2004 , 11, 757-66 | 5.4 | 102 |
| 33 | EphA2 Induction of Fibronectin Creates a Permissive Microenvironment for Malignant Cells. <i>Molecular Cancer Research</i> , 2004 , 2, 533-540 | 6.6 | 24 |
| 32 | Overexpression and functional alterations of the EphA2 tyrosine kinase in cancer. <i>Clinical and Experimental Metastasis</i> , 2003 , 20, 59-68 | 4.7 | 107 |
| 31 | E-Cadherin Binding Modulates EGF Receptor Activation. <i>Cell Communication and Adhesion</i> , 2003 , 10, 105-118 | | 66 |
| 30 | High-level expression of EphA2 receptor tyrosine kinase in prostatic intraepithelial neoplasia. <i>American Journal of Pathology</i> , 2003 , 163, 2271-6 | 5.8 | 99 |

| | | | |
|----|---|------|-----|
| 29 | Differential regulation of EphA2 in normal and malignant cells. <i>American Journal of Pathology</i> , 2003 , 162, 1037-42 | 5.8 | 114 |
| 28 | TEL, a putative tumor suppressor, induces apoptosis and represses transcription of Bcl-XL. <i>Journal of Biological Chemistry</i> , 2003 , 278, 46378-86 | 5.4 | 23 |
| 27 | Predictive value of the EphA2 receptor tyrosine kinase in lung cancer recurrence and survival. <i>Clinical Cancer Research</i> , 2003 , 9, 613-8 | 12.9 | 152 |
| 26 | EphA2 overexpression decreases estrogen dependence and tamoxifen sensitivity. <i>Cancer Research</i> , 2003 , 63, 3425-9 | 10.1 | 51 |
| 25 | Disease stage variation in CD4+ and CD8+ T-cell reactivity to the receptor tyrosine kinase EphA2 in patients with renal cell carcinoma. <i>Cancer Research</i> , 2003 , 63, 4481-9 | 10.1 | 97 |
| 24 | Differential EphA2 epitope display on normal versus malignant cells. <i>Cancer Research</i> , 2003 , 63, 7907-12 | 10.1 | 65 |
| 23 | E-cadherin binding modulates EGF receptor activation. <i>Cell Communication and Adhesion</i> , 2003 , 10, 105-18 | | 38 |
| 22 | Ligand binding up-regulates EphA2 messenger RNA through the mitogen-activated protein/extracellular signal-regulated kinase pathway. <i>Molecular Cancer Research</i> , 2003 , 1, 1070-6 | 6.6 | 13 |
| 21 | Estrogen and Myc negatively regulate expression of the EphA2 tyrosine kinase. <i>Journal of Cellular Biochemistry</i> , 2002 , 85, 714-20 | 4.7 | 41 |
| 20 | Activation of the EphA2 tyrosine kinase stimulates the MAP/ERK kinase signaling cascade. <i>Oncogene</i> , 2002 , 21, 7690-9 | 9.2 | 113 |
| 19 | Regulation of the EphA2 kinase by the low molecular weight tyrosine phosphatase induces transformation. <i>Journal of Biological Chemistry</i> , 2002 , 277, 39274-9 | 5.4 | 108 |
| 18 | Antibody targeting of the EphA2 tyrosine kinase inhibits malignant cell behavior. <i>Cancer Research</i> , 2002 , 62, 2840-7 | 10.1 | 128 |
| 17 | c-Cbl-dependent EphA2 protein degradation is induced by ligand binding. <i>Molecular Cancer Research</i> , 2002 , 1, 79-87 | 6.6 | 102 |
| 16 | Cytometric analysis of cell contact and adhesion. <i>Methods in Cell Biology</i> , 2001 , 63, 599-612 | 1.8 | |
| 15 | Predicting the sites of metastases from lung cancer using molecular biologic markers. <i>Annals of Thoracic Surgery</i> , 2001 , 72, 1144-8 | 2.7 | 69 |
| 14 | Activation of EphA2 kinase suppresses integrin function and causes focal-adhesion-kinase dephosphorylation. <i>Nature Cell Biology</i> , 2000 , 2, 62-9 | 23.4 | 455 |
| 13 | TEL, a putative tumor suppressor, modulates cell growth and cell morphology of ras-transformed cells while repressing the transcription of stromelysin-1. <i>Molecular and Cellular Biology</i> , 2000 , 20, 5828-34 | 4.8 | 93 |
| 12 | The engagement of beta1 integrins on promonocytic cells promotes phosphorylation of Syk and formation of a protein complex containing Lyn and beta1 integrin. <i>European Journal of Immunology</i> , 1999 , 29, 1426-34 | 6.1 | 27 |

| | | | |
|----|--|-----|-----|
| 11 | The engagement of α integrins on promonocytic cells promotes phosphorylation of Syk and formation of a protein complex containing Lyn and α integrin 1999 , 29, 1426 | | 2 |
| 10 | Workgroup 2: human xenograft models of prostate cancer. <i>Prostate</i> , 1998 , 36, 56-8 | 4.2 | 12 |
| 9 | Dynamic interaction of PTPmu with multiple cadherins in vivo. <i>Journal of Cell Biology</i> , 1998 , 141, 287-96 | 7.3 | 152 |
| 8 | Identification of tyrosine phosphorylated adhesion proteins in human cancer cells. <i>Hybridoma</i> , 1998 , 17, 227-35 | | 14 |
| 7 | Rho-stimulated contractility contributes to the fibroblastic phenotype of Ras-transformed epithelial cells. <i>Molecular Biology of the Cell</i> , 1997 , 8, 2329-44 | 3.5 | 143 |
| 6 | The Ras-related protein Rheb is farnesylated and antagonizes Ras signaling and transformation. <i>Journal of Biological Chemistry</i> , 1997 , 272, 10608-15 | 5.4 | 140 |
| 5 | E-cadherin engagement stimulates tyrosine phosphorylation. <i>Cell Adhesion and Communication</i> , 1997 , 4, 425-37 | | 30 |
| 4 | A mechanism for trabecular meshwork cell retraction: ethacrynic acid initiates the dephosphorylation of focal adhesion proteins. <i>Experimental Eye Research</i> , 1997 , 65, 471-83 | 3.7 | 21 |
| 3 | Tyrosine phosphorylation regulates the adhesions of ras-transformed breast epithelia. <i>Journal of Cell Biology</i> , 1995 , 130, 461-71 | 7.3 | 266 |
| 2 | A Reconsideration of University Gap Funds for Promoting Biomedical Entrepreneurship. <i>Journal of Clinical and Translational Science</i> , 1-18 | 0.4 | 0 |
| 1 | FDA-Approved Medicines 1-19 | | |